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ABSTRACT
Pharmacodynamical studies showed that most drugs elicit their effects by acting on 
3 kinds of protein molecules known as receptors, enzymes or transporters. Although 
their detail properties had not been explained for decades the roles of transporters in 
drug kinetics and dynamics has been well understood, even have been applied in the 
therapy. Transporters are classified into 2 major classes, the solute carriers (SLC) and 
ATP-binding cassette (ABC) families. SLC transporters do not possess ATP binding site 
property as those of ABC transporters. SLC transporters consist of 3 SLC subfamilies i.e. 
organic cation transporters (OCTs), organic anion transporters (OATs) and organic anion 
transporting polypeptides (OATPs). In contrast, ABC transporters require ATP hydrolysis 
to transport substrate across cell membrane. Human ABC-transporters consist of ABCA1-
13, ABCB1-11, ABCC1-12, ABCD1-4, ABCE1, ABCF1-3 and ABCG1-8 subfamily. 
Although the originally funtion of transporter is to transport specific physiological 
substrate such as nutrient, hormone, cytokines, neurotransmitters and other physiological 
subtances across cell membrane the specificity is not restricted to each substrate. Drugs 
and other xenobiotics which have structural similarity to the physiological substrates 
are recognized and transported by the related transporters. The competition of them on 
transporters therefore may lead to the occurence of drug-drug interactions (DDI) or drug-
physiological substrate interaction in the drug-kinetics phase. Many transporters located 
in the liver, intestinal and renal epithelial cell membranes involve in the transport of 
endogenous substance or xenobiotics including drugs play important roles as protective 
barrier. Since transporters also serve as the targets of drug action it is understood that 
transporters play important role in the pathogenesis of diseases as well as in the drug 
therapy of diseases.
ABSTRAK
Penelitian farmakodinamik menunjukkan bahwa kebanyakan obat menimbulkan efek 
melalui aksinya pada 3 tempat aksi obat berupa berbagai molekul protein yaitu reseptor, 
enzim dan transporter. Meskipun sudah puluhan tahun karakteristik transporer belum dapat 
diterangkan secara rinci tetapi perannya dalam kinetika dan dinamika obat di dalam tubuh 
telah diketahui dan bahkan telah dipakai sebagai dasar terapi obat. Transporter dapat 
dibagi menjadi 2 kelompok yaitu keluarga solute carriers (SLC) dan ATP-binding cassette 
(ABC). Dalam kerjanya transporter SLC tidak melibatkan ATP seperti pada transporter 
ABC. Transporter SLC terdiri atas 3 subfamili, organic cation transporters (OCTs), organic 
anion transporters (OATs) dan organic anion transporting polypeptides (OATPs). Berbeda 
dari SLC transporter ABC membutuhkan hidrolisis ATP dalam mengangkut substrat 
melewati membran sel. Transporter ABC terdiri atas 8 subfamili yaitu ABCA1-13, ABCB1-
11, ABCC1-12, ABCD1-4, ABCE1, ABCF1-3 dan ABCG1-8. 
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INTRODUCTION
Pharmacodynamical studies during 
the last century revealed that most drugs 
may elicit their effects by acting on 3 kinds 
of protein molecules known as receptors, 
enzymes or transporters. Although the details 
of the mechanism of action had not been 
explained for decades the roles of transporters 
in drug translocation (absorption, distribution 
and excretion) have been known even have 
been applied in the therapy. The use of 
reserpine in the therapy of hypertension to 
inhibit noradrenaline biosynthesis (through 
an inhibition of dopamine uptake into vesicles 
in the sympathetic nerve ending) and the 
use of probenecid to inhibit kidney tubular 
penicillin reabsorption are the examples of 
the involvements of transporters in drug 
pharmacodynamics and pharmacokinetics. 
In the context of translocation it was also 
thought for years that the movement of water 
and small lipid insoluble molecules across cell 
membrane is simply by slipping in through the 
small water filled pores of cell membrane.1-3 In 
fact water transportations across the membrane 
is mediated by aquaporin transporters 
which are grouped into CHIP (channel 
forming integral proteins) transporters that 
generally water selective channels and GLP 
(aquaglyceroporin) transporters that do not 
selective to transport water, glycerol and 
urea.2More attention toward transporters was 
paid after the discovery of P-glycoprotein 
(later is known as multi drug resistance, MDR-
1), the protein which transports anti cancer 
drug out of cancer cell leads to ineffectiveness 
of the drug. Transporters also involve in the 
fail of protease inhibitors to prevent fetal HIV 
infection in HIV infected pregnant woman who 
is treated with the drug.4,5 It is now understood 
that transporter is protein molecule located 
in the cell membrane which plays important 
roles in the transport of substances across cell 
membrane, into or out of cells. The primary 
function of transporter is to cary nutrients 
and endogenous substances such as sugars, 
amino acids, sterol, vitamines, hormone and 
nucleotides across cell membrane. Most 
transporters found in some tissues or organs 
such as liver, kidney, intestine, placenta and 
brain to protect the body from undesired 
dietary or environmental toxins and drugs.6-8
Meskipun secara fisiologis transporter berfungsi mengangkut zat (senyawa) fisiologis 
tertentu seperti nutrien, hormon, sitokin, neurotransmitor dan senyawa fisiologik lain 
melewati membran sel dan bersifat spesifik untuk transporter terkait tetapi spesifitas 
tersebut tidak mutlak. Obat dan zat asing lainnya yang punya kemiripan struktur dengan 
zat fisiologis sebagai substrat transporter tertentu dapat dikenali dan diangkut oleh 
transporter itu. Oleh karena itu kompetisi di antara zat-zat itu pada transporter yang sama 
dapat memunculkan interaksi antara obat satu dengan lainnya atau antara obat dengan 
zat fisiologik tertentu pada fase kinetika obat. Transporter yang terdapat pada membran 
sel hepar, epitel usus dan ginjal yang terlibat dalam transportasi senyawa endogen atau 
zat asing lain seperti obat dapat berperan sebagai sawar untuk organ tertentu. Karena 
transporter juga merupakan tempat aksi obat maka transporter punya peranan sangat 
penting dalam patogenesis penyakit tertentu dan terapinya dengan obat.
Keywords: drug transporters – solute carries – ATP-binding cassette – organic cation 
transporters – organic anion transporting polypeptides 
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DISCUSSION
Classification of Transporters
Transporters can be classified into two 
major classes, the solute carriers (SLC) and 
ATP-binding cassette (ABC) families. SLC 
transporters do not possess ATP binding site 
property as those of ABC transporters. Some 
of them utilize an electrochemical difference 
of substrate transported, known as facilitated 
or primary transporters. Others SLC 
transporters utilize an ion gradient across the 
membrane produced by primary transporters 
against an electrochemical difference, known 
as secondary active transporters.6,8,9 SLC 
transporters consist of 3 SLC subfamilies i.e. 
organic cation transporters (OCTs), organic 
anion transporters (OATs) and organic anion 
transporting polypeptides (OATPs). In 
contrast to SLC, ABC transporters require an 
ATP hydrolysis to transport substrate across 
cell membrane. A variety of physiological 
substances such as sugar, amino acids, 
peptides, nucleotides, lipids, sterols, bile 
salts, endogenous metabolites and xenobiotics 
are transported by these transporters. Drugs 
that structurally resemble to the substrates 
are recognized and also transported by these 
transporters.10 The best studied of ABC drug 
transporters are multi drug resistance (MDR), 
multi drug resistance associated protein (MRP) 
and breast cancer resistance protein (BCRP), 
however most drug transporters belong to 
the SLC family.6,11 It is known that human 
ABC-transporters consist of ABCA1-13 
subfamily, ABCB1-11, ABCC1-12, ABCD1-
4, ABCE1, ABCF1-3 and ABCG1-8.12-14 
Some of them responsible for the occurrence 
of drug resistances, they are ABCB1 (MDR1), 
MRP1-7 (ABCC1-6 and ABCC10), BCRP or 
ABCG2 transporters.6,10,11,15Transporters are 
also classified according to the direction of the 
transfer of substrates mediated by transporters 
as influx versus efflux transporters, and 
absorptive versus secretory transporters. 
Influx transporters transfer substrates into 
cell where as efflux transporters transfer 
substrates out of cell. Transporter that 
drives its substrates into systemic blood 
circulation is called absorptive transporter, 
and transporter that transfers substrates 
from blood circulation into bile, urine or gut 
lumen is known as secretory transporter. It is 
therefore, modifications have to be applied for 
placental and blood brain barrier since in the 
human body brain and fetus are considered 
to as isolated compartments. Transporter 
that facilitates penetration of substrates 
(physiological substances or drugs) into the 
brain or fetus is an absorptive transporter 
although the substrates are transported from 
blood circulation. Contrary, transporter which 
transports substrates from the brain or fetus 
into blood stream is a secretory transporter 
although it transfers substrates into blood 
circulation.6 It is also thought therefore, that 
an absorptive transporter does not always 
mean an influx transporter, and a sectretory 
transporter does not always an efflux 
transporter. OAT1 transporter for example, 
located at the membrane of kidney proximal 
tubule cell is an influx transporter since it 
transports drugs from circulating blood into 
proximal tubule cell then are transported 
(efflux) leaving proximal tubule cell into 
urine for elimination. Although it transports 
drugs into proximal tubule cell however, the 
OAT1 is a secretory transporter based on its 
overall roles of removing drugs out of blood 
circulation. In contrast, OATP-A located at 
apical membrane of enterocyte which take up 
(as influx transporter) orally given drug into 
the cell for their subsequent exit across the 
basal membrane into blood stream, therefore 
OATP-A is an absorptive transporter. From the 
explanation, influx transporter can function 
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as either absorptive or secretory transporter 
depend on the tissue and the membrane domain 
where they are expressed.6 Identified human 
OATPs consists of OATP1A2, OATP1B1, 
OATP1B3, OATP1C1, OATP2A1, OATP2B1, 
OATP3A1, OATP4A1, OATP4C1, OATP5A1, 
OATP6A1 which are localized in brain, liver, 
kidney and testis. OATPs identified in mouse 
and rats are Oatp1a1, Oatp1a2, Oatp1a3, 
Oatp1a4, Oatp1a5, Oatp1a6, Oatp2a1, 
Oatp2b1, Oatp4a1, Oatp4c1, Oatp5a1, and 
Oatp56a1.8 Other human SLC transporters 
consist of OCTs and MATE (multidrug and 
toxin extrusion) transporters. Expression 
of human OCT1 and OCT2 are restricted 
to the liver and kidney respectively while 
OCT3 is more widely distributed whereas 
MATEs are predominantly expressed in 
kidney.16Transporters for water and small lipid 
insoluble molecules were first identified as 
channel forming integral proteins (CHIP28) 
since their molecular weight were 28kDa17,18 
and also known as aquaporin-1 (AQP1). Later 
studies revealed that aquaporin, trasporters for 
water and other small lipid insoluble molecules 
can be grouped into CHIP group of aquaporin 
(AQP0, AQP1, AQP2, AQP4, AQP5, AQP6, 
and AQP8 transporters) which are generally 
water channels and GLP (aquaglyceroporin) 
group transporters (AQP3, AQP7, AQP9, and 
AQP10) which are not selective for water, 
glycerol and urea.2
Transporters and Pathogenesis of Diseases
As has been mention before, transporter 
plays important roles in the transport of 
nutrients, endogenous substances and 
xenobiotics including drugs. An abnormality 
or defect of its nature (structure and other 
properties) may cause physiological 
disturbances leads to the occurrence of diseases 
or causes changes in drug pharmacokinetics 
leads to the occurrence of drug ineffectivenes 
or toxicity. Mutations in ABC transporter 
genes have been associated to several 
genetic diseases such as cystic fibrosis, a 
disease associated with mutation of ABCC7 
or CFTR (cystic fibrosis transmembrane 
conductance regulator). It consists of an 
exocrine pancreatic insufficiency, increase 
of sweat NaCl content, male infertility and 
respiratory disease.12,19,20 CFTR is membrane 
cAMP-activated Cl- channel which is 
expressed in several tissue including kidney, 
pancreas, heart, intestine, vas deferens, sweat 
duct and lung. In the epithelial cells of these 
organs CFTR mediates the secretion of Cl-, 
Na+ and K+ through the channels or anion 
exchangers, Na-bicarbonate transporters and 
aquaporin water channels. Mutation in CFTR 
gene affects the number of channels in the 
membranes, channel activity and intracellular 
trafficking of CFTR. Other diseases which 
also linked to ABC transporters are Dubin–
Johnson Syndrome (mutations of ABCC2), 
age-related macular degeneration (ABCA4 
mutation), Tangier disease (mutations of 
ABCA1) and sitosterolaemia which is linked 
to mutations in ABCG5 and ABCG8.19,20 
ABCA1 transporter is a cholesterol exporter 
that highly expressed in the liver and tissue 
macrophages to transport cholesterol, 
phospholipids and other metabolites from 
cells to lipid depleted HDL-apolipoproteins 
initiates formation of HDL particles. ABCA1 
therefore, may prevent cardiovascular 
disease. Other ABC transporters which 
have the same roles in the prevention of 
cardiovascular diseases are ABCA7, ABCG1 
and ABCG4. ABCA7, a homolog of ABCA1 
also selectively transports phospholipids 
to lipid-depleted apolipoproteins leads to 
formation of HDL. ABCG1 transporters (in 
tissue macrophage) and ABCG4 (in brain 
cells) mediate choletsterol transport from 
cells to HDL particles.21-23 It is recognized 
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that mutation of ABCA1 may cause Tangier 
disease, a rare HDL deficiency syndrome.19,21 
ABC transporters now have been associated 
with a specific disease, progressive familial 
intrahepatic cholestasis type-2 (PFIC2) 
caused by mutation of ABCB11 transporter 
gene leads to lost of its function.6,24 The 
ABCB4 transporter is also thought to play an 
important role in the liver since in the absence 
of ABCB4 the detergent activity of bile salts 
(transported into bile by ABCB11) solubilize 
cell membranes leads to biliary toxicity. The 
evidence indicated that homozygous mutation 
of ABCB4 causes PFIC3 (progressive familial 
intrahepatic cholestasis type-3) occures within 
the first few years of age and characterized by 
pruritus, jaundice and growth restriction. It 
is thought therefore the mutations of ABCB4 
is associated with a cholestatic diseases.24A 
side effect of statin as rhabdomyolysis 
may occurred in genetic abnormal variant 
of OATP1B1 which is expressed in liver. 
Abnormality of OATP1B1 may cause an 
increase of statin blood concentration leads 
to the occurrence of myopathy.9 Other SLC 
transporters OAT1, which is expressed in 
renal tubular cells mediates the transportation 
of many drugs such as digoxin, betalactam 
antibiotics, nonsteroidal anti-inflammatory 
drugs and antiviral cidofovir. The use of 
cidofovir for cytomegalovirus rhinitis in 
AIDS patient may cause nephrotoxicity due 
to intensive uptake of the drug by OAT1 
transporter. However the toxicity can be 
prevented by co-administration of probenecid 
which is also transported by OAT1 transporter 
leads to a decrease cidofovir renal clearance 
and its nephrotoxicity effect.25
Transporters and Pharmacotherapy
Although the originally role of transporter 
is to transport specific physiological substrate 
across cell membrane the specificity is not 
restricted to each substrate. Drugs and other 
xenobiotics which have structural similarity 
to the physiological substrates therefore are 
recognized and transported by the related 
transporters.6-8 The competition of them 
on transporters therefore may lead to the 
occurence of drug-drug interactions (DDI), 
or drug-physiological substrate interaction in 
the drug-kinetics phase.6,8,9 Many transporters 
located in the liver, intestinal and renal 
epithelial membrane cells involve in the 
transport of endogenous substance or drugs 
play important roles in the tissue selective 
absorption, distribution and elimination 
of them but may also play important roles 
as protective barrier to particular cells or 
organ.26 The transporters therefore may also 
play roles as the targets of drug action lead 
to the alteratiom of pathogenesis of diseases 
and the therapy of diseases.27,28In the therapy 
of diabetes melitus for example, the use of 
metformin to decrease blood glucose level 
is based on the effects of metformin to 
increase cellular insulin sensitivity lead to 
the increase of cellular uptake and usage of 
glucose.29 Cellular uptake of metformin which 
is mediated by OCT1 transpoter is increased 
by rifampin which stimulates pregnane-x 
receptor to increase hepatocyte OCT1 
expression lead to metformin acumulation 
and increase of its blood glucose lowering 
effect. Since OCT1 was also observed in 
subcutaneous and visceral adipose tissue and 
the OCT1 expression increase in the obese, 
it is suggested that the mechanism may take 
account for better effect of metformin in the 
obese subjects.28 It is known that probenecid 
can increase blood penicillin level since in the 
excretion process of both drugs are mediated 
by the same tubular transporter (OAT3) lead to 
an increase of the effectiveness of penicillin in 
the therapy. Since methotrexate and antiviral 
drug adefovir are also transported by OAT3 
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it is suggsted therefore to avoid the use of 
NSAIDs and those drugs in a combination 
therapy to prevent nephrotoxicicity caused 
by adefovir.28The use of statin in the therapy 
of hyperlipidemia and the role of related 
transporter are extensively studied. OATP1B1 
(previously known as OATP-C, OATP-2 and 
LST-1) found in basolateral membrane of 
hepatocytes plays important roles in the uptake 
of statin and OAD (oral antidiabetics). The 
OATP1B1 is highly polymorphism and 15% of 
Asian and Caucasian have abnormal function 
of OATP1B1 transporter lead to an improper 
statin uptake. Since the target molecule of 
statin is 5-hydroxy-3-3-methylglutaryl-
coenzyme A (HMG-coA) reductase enzyme 
in the liver, abnormal function of OATP1B1 
transporter may cause ineffectiveness of statin 
therapy in such patient. Is is thought therefore 
OAD may decrease the lipid lowering 
effect of statin.26,28 Other SLC transporter, 
OATP2B1 or SLCO2B1 (previously known 
as OATP-B) found in apical membrane 
of enterocytes involves in montelukast (a 
leukotriene receptor antagonist) and aliskiran 
(found in apple, orange and grapefruit juice) 
transportation. For that reason, in the therapy 
of bronchial asthma it is adviced therefore to 
avoid taking the juice at the same time with 
the orally montelukast.29ABC transporters 
which were identified originally for the ability 
to extrude anticancer drugs lead to the fail of 
therapy play important roles in DDI (drug-
drug interaction). MDR1 (ABCB1 transporter, 
P-glycoprotein) is particularly important in 
the extrude of drugs (such as for digoxin, 
atorvastatin, HIV-1 protease inhibitors, 
cyclosporin, verapamil, clarithromycin and 
talinolol) back into the intestinal lumen and 
effectively limit the extent of absorption and 
bioavailability the drugs. Since digoxin is 
high affinity substrate for intestinal MDR1 
it is thought therefore to increase digoxin 
bioavailability by coadministeration digoxin 
with the mentioned drugs, or in other hand there 
must be very careful calculation if such drugs 
have to be given as a combination with digoxin 
to prevent digoxin intoxication.27Some ABC 
superfamily transporters involve and play 
important role in drug kinetics and the drugs 
may be transported by the same transporter. 
From this viewpoint, again, the use of few 
drugs in a combination has to be carefully 
considered, to increase the efficaciousness of 
therapy as well as to prevent drug toxicity in 
the other hand. BCRP (ABCG2) transporter 
which is expreesed in the gastrointestinal tract, 
liver, kidney, brain epndothelium, mammary 
tissue, placenta and testis plays roles in 
limiting certain oral bioavailability and drug 
transport across blood brain and placental 
barrier for drugs although the physiological 
functions of BCRP transporter are the 
extrusion of porphyrins from haemapoeitic 
cells and hepatocytes, as well as the secretion 
of riboflavin (vitamin B2), biotin and vitamin 
K into breast milk. Subject belong to ABCG2 
variant may suffering from drug intoxication 
such particularly drugs which have narrow 
therapeutic range.7,26,30
CONCLUSION 
Transporters are protein molecules which 
play important roles in driving substances 
such as nutrient, neurotransmitters, cytokines 
and other physiological substances across 
cell membrane. They are classified into 
SLC and ABC transporters superfamilies, 
each transports a specific substarte across 
membrane cell into (influx) or out of 
(efflux) the cell. Although the original 
funtion of transporter is to transport specific 
physiological substrate, drugs and other 
xenobiotics which have structural similarity to 
the substrates are recognized and transported 
by the related transporters. The competition 
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of them on transporters therefore may lead to 
the occurence of drug-drug interactions (DDI) 
or drug-physiological substrate interaction 
in the drug-kinetics phase and alter the 
pharmacodynamics of the drug. 
Since transporters also serve as the targets 
of drug action it is understood therefore 
that transporters play important role in the 
pathogenesis of diseases as well as in the drug 
therapy of diseases. The understanding of the 
type, function and distribution of thransporters 
will increase our ability to predict or make 
calculation of the effectiveness, efficaciourness 
and safety of drugs used in the therapy 
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